BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
New 'People We Meet on Vacation' trailer teases Poppy and Alex romance: Everything we know about the new Netflix movie - 2Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- 3German hauliers warn soaring energy prices may soon impact consumers
- 4Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- 5Journey Travel Objections for Your Next Experience
- The Best 15 Applications for Efficiency and Association
- Amid growing bipartisan scrutiny of Pete Hegseth, Trump says he 'wouldn't have wanted … a second strike' on alleged Venezuelan drug boat survivors
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Key Training: Picking a Significant for Monetary Achievement
- Share your pick for the riding area that characterizes your surf undertakings!
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Working out at the airport? Some fliers can already smell the sweat.
- From Specialist to Proficient Picture taker: Individual Triumphs
